By Dhirendra Tripathi

Investing.com – Johnson & Johnson stock (NYSE:) traded 1.4% lower in premarket a day after cases of blood clotting associated with the company’s Covid-19 vaccine prompted the CDC to recommend Americans to choose between mRNA shots made by Pfizer (NYSE: Moderna (NASDAQ:).

The Advisory Committee on Immunization recommended that the CDC move.

With only around 16 million of the 200 million fully-vaccinated American receiving J&J’s vaccine and the company selling it at a not-for-profit price, the revenue impact on the company’s accounts so far has been negligible. It is unlikely that it will contribute more cash to future cash flows, according to the CDC.

In more adverse news for the company, members of the panel also said that J&J’s vaccine is less effective in stopping the virus than the other two vaccines.

J&J said in a statement that the safety and well-being of those who use its vaccine is its top priority and it looks forward to working with the CDC on the next steps.

Blood clots accompanied by low levels of platelets have previously been reported in recipients of the J&J vaccine.

Following similar recommendations in other countries (Canada and the U.K.), the updated CDC recommendation was published.

ACIP and CDC both reiterated that getting any vaccine is preferable to not being vaccinated. Individuals who are unable or unwilling to receive an mRNA shot will continue to have access to J&J’s vaccine, the CDC said.

J&J’s is the only single-shot vaccine available in the U.S. while the other two are double-dose.

The company disclosed last month its plans to separate its consumer-health business and list it separately. It is estimated that this process will take anywhere from 18-24 months.